Start here if you're new
what it is
NextCure is a 43-person biotech that tries to kill cancer cells with antibody-drug conjugates.
how it gets paid
Last year Nextcure made n/a in revenue. ADC programs was the main engine at $0, or 25% of sales.
what just happened
NextCure's latest quarter showed -$18.84 EPS and no reported revenue.
At a glance
C balance sheet — red flag territory — real financial stress
70/100 earnings predictability — reasonably predictable
-$23.89 fy2024 eps est
1.2 beta
~$45M market cap
xvary composite: 39/100 — weak
What they do
NextCure is a 43-person biotech that tries to kill cancer cells with antibody-drug conjugates.
The edge here is not sales. It is a narrow science bet built by 43 employees. That means your money rides on lab data, not store traffic. If one program works, the stock can react fast. If it does not, there is no revenue base to cushion the hit.
How they make money
n/a
annual revenue
ADC programs
$0
Biomarker research
$0
Partnerships
$0
Corporate and other
$0
The products that matter
lead wholly owned adc
NC410 (LAIR-2 ADC)
Phase 1 · data due Q2 2026
this is the lead internal asset, and Phase 1 data is expected in Q2 2026. with $0 revenue today, that readout carries more weight than any quarterly sales number you could possibly get.
lead catalyst
partnered adc program
SIM0505
50-50 cost share · data due 2H 2026
this partnered candidate spreads development cost 50-50 with Simcere Zaiming, which matters for a company burning cash. the trade is simple: you cut the bill in half and you cut the upside in half too.
shared economics
Key numbers
-$23.89
fy2024 eps est
n/a
fy rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
C
strength
- balance sheet grade C — very weak — significant financial distress
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $4M (9% of capital)
C — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for NXTC right now.
source: institutional data · return history unavailable
What just happened
missed estimates
NextCure's latest quarter showed -$18.84 EPS and no reported revenue.
EDGAR shows no revenue and a quarterly EPS loss of -$18.84. That is the whole story in one line: a pre-revenue biotech still spending money to chase data.
-$18.84
eps
n/a
n/a
n/a
n/a
the number that mattered
The -$18.84 EPS loss matters because it shows the company is still deep in the red with no revenue to soften it.
source: EDGAR filing and company earnings report, latest quarter
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk here is clinical failure in NC410's Q2 2026 Phase 1 readout. with $0 revenue and no approved products, weak data would hit both the science case and the financing case at the same time.
med
NC410 disappoints
NXTC has $0 revenue and no approved products. If the Q2 2026 data fails to show a credible signal, the lead wholly owned asset loses much of its value fast.
The company would still have the burn rate, but less reason for investors to fund it on today's terms.
med
cash burn forces dilution
A $55.8M loss in 2025 and runway only into 1H 2027 make another raise a timing question, not a theoretical one.
Even good science can be a weak stock if too many new shares show up before the data does.
med
partner economics cap the upside
SIM0505 spreads cost with Simcere Zaiming on a 50-50 basis. That protects the runway, but it also means one of the few visible assets is not fully yours even if it works.
You get less financial strain and less winner's payoff. Both are true at the same time.
With $0 revenue and runway into 1H 2027, this is a race between biology and the balance sheet.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
NC410 Phase 1 data in Q2 2026
This is the lead wholly owned asset and the next major proof point. If you only watch one date, watch this one.
trend
SIM0505 readout in 2H 2026
A positive result would help validate the pipeline, but remember the economics are shared 50-50.
metric
cash burn versus the 1H 2027 runway
The 2025 loss was $55.8M. If spending stays near that level, financing pressure does not disappear because one private placement already happened.
risk
another raise before the science settles
A new financing before the key datasets land would remind you what this stock is: a capital-markets story attached to an R&D program.
Analyst rankings
earnings predictability
70 / 100
in human-speak, the losses are predictable because there is no revenue engine yet — but the stock still is not predictable.
beta
1.2
When the market moves, NXTC has tended to move a bit more. Add a 5 / 100 price stability score and you get the part that matters.
source: institutional data
Institutional activity
institutional ownership data for NXTC is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$12
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive